The effect of sodium glucose cotransporter 2 inhibition with empagliflozin on microalbuminuria and macroalbuminuria in patients with type 2 diabetes.
about
Effects of sodium-glucose co-transporter 2 (SGLT2) inhibition on renal function and albuminuria in patients with type 2 diabetes: a systematic review and meta-analysis.Sodium-Glucose Cotransporter 2 Inhibitors with Renoprotective Effects.Effects of sodium-glucose cotransporter 2 inhibitors on urinary excretion of intact and total angiotensinogen in patients with type 2 diabetes.Sodium-glucose co-transporter type 2 inhibitors reduce evening home blood pressure in type 2 diabetes with nephropathy.The albuminuria-lowering response to dapagliflozin is variable and reproducible among individual patients.Cardioprotective effects of SGLT2 inhibitors are possibly associated with normalization of the circadian rhythm of blood pressure.Dapagliflozin: potential beneficial effects in the prevention and treatment of renal and cardiovascular complications in patients with type 2 diabetes.Renal Effects of SGLT-2 Inhibitors and Other Anti-diabetic Drugs: Clinical Relevance and Potential Risks.Effects of glycaemic management on diabetic kidney disease.Diabetes Mellitus Following Renal Transplantation: Clinical and Pharmacological Considerations for the Elderly Patient.Linagliptin and its effects on hyperglycaemia and albuminuria in patients with type 2 diabetes and renal dysfunction: the randomized MARLINA-T2D trial.Comparative effectiveness and safety of empagliflozin on cardiovascular mortality and morbidity in adults with type 2 diabetes.Dapagliflozin in Focal Segmental Glomerulosclerosis: A Combined Human-Rodent Pilot Study.Role of the sodium-hydrogen exchanger in mediating the renal effects of drugs commonly used in the treatment of type 2 diabetes.Un-sweetening the Heart: Possible pleiotropic effects of SGLT2 inhibitors on cardio and cerebrovascular alterations in resistant hypertensive subjects.Impacts of sodium-glucose co-transporter type 2 inhibitors on central blood pressure.The Effect of Sodium-Glucose Co-transporter-2 (SGLT-2) Inhibitors on Cardiometabolic Profile; Beyond the Hypoglycaemic Action.New Diabetes Therapies and Diabetic Kidney Disease Progression: the Role of SGLT-2 Inhibitors.Differential Effects of Dapagliflozin on Cardiovascular Risk Factors at Varying Degrees of Renal Function.Recovery from Diabetic Macular Edema in a Diabetic Patient After Minimal Dose of a Sodium Glucose Co-Transporter 2 Inhibitor.Comprehensive renoprotective effects of ipragliflozin on early diabetic nephropathy in mice.SGLT-2 Inhibitors and Cardiovascular Protection: Lessons and Gaps in Understanding the Current Outcome Trials and Possible Benefits of Combining SGLT-2 Inhibitors With GLP-1 Agonists.Systematic review and meta-analysis of the effect of SGLT-2 inhibitors on microvascular outcomes in patients with type 2 diabetes: a review protocol.Effect of Canagliflozin on Urinary Albumin Excretion in Japanese Patients with Type 2 Diabetes Mellitus and Microalbuminuria: A Pilot StudyTherapeutic potential of tofogliflozin on nephrotic syndrome secondary to diabetic nephropathy
P2860
Q32186373-526380C7-F28A-41F1-9FB0-634EEDDB4ABDQ38635763-CB558455-8AFE-4CBB-8CC7-0C458A7CD7ECQ38735470-BF5084B9-C6E6-4247-B17D-25B14E2513F2Q38807217-782D1F25-1922-4150-843D-D662FC30625FQ38906470-EFFE9611-3E1D-4B2D-B2CD-F069857417E6Q39013664-6D746682-E4E1-4176-8EEA-DE8BB7649411Q39170860-C39B3668-A081-47D9-A9B2-F6E52D7D332AQ39290337-9F54291F-9A8E-4A19-9DDB-96DE5376CBB3Q39345204-B15C5FF9-DC6F-48AA-B358-BDBC4A80E967Q39441009-D0B04ECB-BA78-4061-9A13-599A8085BC3AQ43742584-281D1BA4-6B0E-41BE-BB90-22B260048E52Q47236288-ED7D159F-DC3F-43F4-B5CD-18B8E7FC6F77Q47398861-99428E41-B822-455C-9FC0-DD831F3C776CQ48141985-250FB176-D725-49C8-8C14-66692980EE66Q49550551-3CF5BC2E-43A6-4B4D-B378-3EA0D38C9E6EQ49719259-F8940C2A-023D-4D09-8B74-13F70ADC7B8FQ51034590-99508172-C852-4B44-BDB3-462B4468EA75Q51733588-DB668EBB-B9E0-46A2-A89A-C1D01590DD04Q52889769-1920841E-06FB-4B22-A7C2-B013E9DF4562Q53693977-9A65BF8F-869A-4B12-B437-6F7136BF0D61Q55174679-7A4919B8-6675-4FB4-AD74-444603EBA356Q55411384-53152CB0-4D9B-46C6-8327-ECA7C6893F4EQ55669037-C7F0C897-8CB7-4D83-A881-4E27E3B6A5CDQ57136996-C001729D-FD61-4552-9334-D59280B363E0Q57153398-29A03501-8A32-42D8-9C09-EC0D04F8DA62
P2860
The effect of sodium glucose cotransporter 2 inhibition with empagliflozin on microalbuminuria and macroalbuminuria in patients with type 2 diabetes.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
The effect of sodium glucose c ...... patients with type 2 diabetes.
@en
The effect of sodium glucose c ...... patients with type 2 diabetes.
@nl
type
label
The effect of sodium glucose c ...... patients with type 2 diabetes.
@en
The effect of sodium glucose c ...... patients with type 2 diabetes.
@nl
prefLabel
The effect of sodium glucose c ...... patients with type 2 diabetes.
@en
The effect of sodium glucose c ...... patients with type 2 diabetes.
@nl
P2093
P1433
P1476
The effect of sodium glucose c ...... patients with type 2 diabetes.
@en
P2093
Bruce A Perkins
David Cherney
Egon Pfarr
Hans J Woerle
Mark E Cooper
Maximilian von Eynatten
Stefan Kaspers
Søren S Lund
P2888
P304
P356
10.1007/S00125-016-4008-2
P577
2016-06-17T00:00:00Z